Aurobindo's Apitoria unit wins FDA VAI rating for India API plant
Apitoria Pharma, a unit of Aurobindo Pharma, received a VAI rating from the US FDA for its Andhra Pradesh API plant after an August inspection.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
On November 21, Aurobindo Pharma informed the exchange that Apitoria Pharma, its fully held unit, has been assigned the Voluntary Action Indicated (VAI) status by the US Food and Drug Administration. The rating covers the active ingredient plant at Unit-VI in E-Bonangi village, Anakapalli district, Andhra Pradesh, which the regulator inspected from August 24 to August 28, 2026.
The inspection produced three observations. The company has now received the Establishment Inspection Report, and the review has been closed. TradingView reported the details, adding that Aurobindo shares closed slightly lower at ₹1,799 on the NSE on November 20.
why it matters
VAI means the FDA found issues the company should fix on a voluntary basis, and for now it does not plan enforcement based on this inspection. That is better than an OAI rating, which can trigger regulatory action. Still, VAI is not a clean bill of health, since the three observations must be resolved.
market impact
Aurobindo Pharma shares: lower regulatory risk at a key plant supports the stock.
- Aurobindo Pharma shares pressure up — lower risk of FDA enforcement at its Andhra Pradesh plant
tags
instruments
sources
- Aurobindo Pharma's Apitoria unit gets 'voluntary action indicated' classification from USFDA — TradingView, 21 November 2026 at 08:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗